4.7 Editorial Material

In hemophilia, it just keeps getting better Comment

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Hematology

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Michael U. Callaghan et al.

Summary: Long-term data from pooled studies show that prophylaxis with emicizumab maintains low bleed rates in persons with hemophilia A of all ages, with good tolerability and no new safety concerns.
Article Medicine, General & Internal

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

J. Mahlangu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Medicine, General & Internal

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)